AC Immune SA (NASDAQ: ACIU) stock is trading up 143.4% to $17.80 in the morning session today. A closer look at the stock price shows that it is currently trading 43.61% above its three-month low. Taking a broader perspective, the stock is trading at a 28.12% discount to its 52-week high and 129.59% above its 52-week low.
Company Info.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Nasdaq-listed AC Immune SA (NASDAQ: ACIU) aims to become the world’s leading precision drug company for neurodegenerative diseases. In addition to designing and developing small molecule and biological therapeutics, the Company uses two proprietary platforms, SupraAntigen and Morphomer, to diagnose, prevent and treat neurodegenerative diseases caused by misfolded proteins.
Latest Development
February 11, 2021, AC Immune SA (NASDAQ: ACIU) has reported positive preliminary results from Phase 1b/2a clinical trials examining ACI-35.030 as a potential first-in-class treatment Alzheimer’s disease (AD). Antigen-specific antibodies were generated against pTau in 100% of elderly patients with early AD following vaccination with ACI-35.030, leading to antibody levels 1000 times higher than pre-vaccination levels. These results suggest that ACI-35.030 could treat AD as they observed no clinically relevant adverse events. AC Immune and its strategic partner Janssen Pharmaceuticals, Inc., believe these interim findings support their plans to further develop this drug.
The anti-Tau vaccine represents a novel treatment approach for treating Alzheimer’s disease and other neurodegenerative diseases characterized by Tau pathology. ACI-35.030 is a unique vaccine candidate that targets pTau proteins in the brain to produce a specific antibody response. An antibody derived from ACI-35.030 may reduce pTau pathology, a major hallmark of AD.
The new results show that ACI-35.030 works well in patients with compromised immune systems using a new vaccine formulation that has been demonstrated to achieve increasing antibody response levels. Anti-pTau vaccination produces antibody responses that differ considerably from the Company’s anti-Tau monoclonal antibody semorinemab, showing how exhaustive and complimentary AC Immune’s anti-Tau pipeline is.
Conclusion
During an era of medical science where fresh ways are being discovered to treat and prevent diseases previously unimaginable, biotech stocks allow investors to make a killing.
